BR0308144A - Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto - Google Patents

Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto

Info

Publication number
BR0308144A
BR0308144A BR0308144-3A BR0308144A BR0308144A BR 0308144 A BR0308144 A BR 0308144A BR 0308144 A BR0308144 A BR 0308144A BR 0308144 A BR0308144 A BR 0308144A
Authority
BR
Brazil
Prior art keywords
compound
hydroxy
halo
alkyl
hydrogen
Prior art date
Application number
BR0308144-3A
Other languages
English (en)
Inventor
Paul Robert Owen Whittamore
Stuart Norman Lile Bennett
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0308144A publication Critical patent/BR0308144A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". Amidas heterocíclicas da fórmula (1) em que: é uma ligação simples ou dupla; A é fenileno ou heteroarileno; m é 0, 1 ou 2; n é 0, 1 ou 2; R^ 1^ é selecionado, por exemplo, a partir de halo, nitro, ciano, hidróxi, carbóxi; r é 1 ou 2; Y é -NR^ 2^R^ 3^ ou - OR^ 3^; R^ 2^ e R^ 3^ são selecionados a partir de, por exemplo, hidrogênio, hidróxi, arila, heterociclila e alquila C~ 1-4~ (opcionalmente substituído por 1 ou 2 grupos R^ 8^); R^ 4^ é selecionado, por exemplo, a partir de hidrogênio, halo, nitro, ciano, hidróxi, alquila C~ 1-4~ e alcanoíla; R^ 8^ é selecionado, por exemplo, a partir de hidróxi, -COCOOR^ 9^, -C(O)N(R^ 9^)(R^ 10^), -NHC(O)R^ 9^, (R^ 9^) (R^ 10^)N- e -COOR^ 9^; R^ 9^ e R^ 10^ são selecionados, por exemplo, a partir de hidrogênio, hidróxi, alquila C~ 1-4~ (opcionalmente substituido por 1 ou 2 R^ 13^); R^ 13^ é selecionado a partir de hidróxi, halo, trialometila e alcóxi C~ 1-4~; ou um sal farmaceuticamente aceitável ou pró-droga dos mesmos; possuem atividade inibitória de glicogênio foforilase e portanto possuem valor no tratamento de estados de doença associados com atividade de glicogênio fosforilase aumentada. Processos para a manufatura dos referidos derivados de amida heterocíclica e composições farmacêuticas contendo os mesmos são descritos.
BR0308144-3A 2002-03-06 2003-03-04 Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto BR0308144A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0205176.1A GB0205176D0 (en) 2002-03-06 2002-03-06 Chemical compounds
PCT/GB2003/000883 WO2003074484A1 (en) 2002-03-06 2003-03-04 Indolamid derivatives which possess glycogenphosphorylase inhibitory activity

Publications (1)

Publication Number Publication Date
BR0308144A true BR0308144A (pt) 2004-12-07

Family

ID=9932340

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308144-3A BR0308144A (pt) 2002-03-06 2003-03-04 Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto

Country Status (20)

Country Link
US (1) US7138415B2 (pt)
EP (1) EP1483240A1 (pt)
JP (1) JP2005524667A (pt)
KR (1) KR20040097145A (pt)
CN (1) CN100374420C (pt)
AR (1) AR038889A1 (pt)
AU (1) AU2003216988A1 (pt)
BR (1) BR0308144A (pt)
CA (1) CA2477717A1 (pt)
GB (1) GB0205176D0 (pt)
IL (1) IL163823A0 (pt)
IS (1) IS7435A (pt)
MX (1) MXPA04008612A (pt)
NO (1) NO20044032L (pt)
NZ (1) NZ534683A (pt)
PL (1) PL373872A1 (pt)
RU (1) RU2004125182A (pt)
TW (1) TW200304817A (pt)
WO (1) WO2003074484A1 (pt)
ZA (1) ZA200406681B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
JP2006507294A (ja) 2002-11-07 2006-03-02 ファイザー・プロダクツ・インク 抗糖尿病剤
GB0318464D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020985A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US20090124682A1 (en) * 2005-02-05 2009-05-14 Alan Martin Birch Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
SG10201901192TA (en) * 2014-09-10 2019-03-28 Epizyme Inc Smyd inhibitors
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
CN114403150B (zh) * 2022-02-09 2022-11-04 中国农业大学 一种吲哚酰胺类化合物作为海藻糖-6-磷酸合成酶抑制剂的应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE200740C (pt)
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
DE3304019A1 (de) 1983-02-07 1984-08-09 Kali-Chemie Pharma Gmbh, 3000 Hannover 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
GB8522574D0 (en) * 1985-09-12 1985-10-16 Lepetit Spa Amides of teicoplanin compounds
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4791112A (en) * 1987-02-02 1988-12-13 The Boc Group, Inc. N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
JPH02124756A (ja) 1988-07-27 1990-05-14 Suzuki Sangyo Kk セメンティング組成物
JPH04179949A (ja) 1990-11-15 1992-06-26 Fuji Photo Film Co Ltd 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料
CA2137832C (en) 1992-06-12 2000-09-26 Dennis J. Hoover Inhibitors of angiotensin i chymase(s) including human heart chymase
ES2081747B1 (es) 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
WO1995024391A1 (en) 1994-03-09 1995-09-14 Novo Nordisk A/S Piperidines and pyrrolidines
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
DE4445968A1 (de) 1994-12-22 1996-06-27 Bayer Ag Verwendung von Sulfonylguanazinen
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
ES2164151T3 (es) 1995-06-06 2002-02-16 Pfizer N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa.
MX9709874A (es) 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
WO1997009040A1 (en) * 1995-09-08 1997-03-13 Novo Nordisk A/S 2-alkylpyrrolidines
AU2090897A (en) 1996-02-29 1997-09-16 Mikael Bols Hydroxyhexahydropyridazines
JP2000511173A (ja) 1996-05-27 2000-08-29 藤沢薬品工業株式会社 一酸化窒素産生阻害剤としての新規なインドリルおよびベンゾフラニルカルボキサミド
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
AU6291098A (en) 1997-03-07 1998-09-29 Novo Nordisk A/S Novel heterocyclic compounds
HUP0003362A3 (en) 1997-05-06 2001-04-28 Novo Nordisk As Piperidine derivatives and pharmaceutical compositions containing them
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (en) 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
EP1150674A1 (en) 1999-02-12 2001-11-07 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
US6043091A (en) 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
WO2001023347A1 (en) 1999-09-29 2001-04-05 Novo Nordisk A/S Novel aromatic compounds
PT1088824E (pt) 1999-09-30 2004-04-30 Pfizer Prod Inc Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
ATE318809T1 (de) 1999-11-05 2006-03-15 Sod Conseils Rech Applic Heterocyclische verbindungen und ihre verwendung als medikamente
ES2433476T3 (es) 2000-01-21 2013-12-11 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GT200100039A (es) 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
ES2218338T3 (es) 2000-04-13 2004-11-16 Pfizer Products Inc. Efecto sinergico de gliburida y milrinona.
NZ523034A (en) 2000-06-09 2004-07-30 Aventis Pharma Gmbh Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
IL144507A0 (en) 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
ES2254492T3 (es) * 2000-09-19 2006-06-16 Moses Lee Composiciones y procedimientos de uso de analogos aquirales de cc-1065 y de duocarmicinas.
AU2001288110A1 (en) 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
JPWO2002036583A1 (ja) 2000-11-01 2004-03-11 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗性医薬組成物
US20030147866A1 (en) 2001-04-04 2003-08-07 Nicolette Charles A. Novel BGP compounds for therapy and diagnosis and methods for using same
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
JP2005506956A (ja) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CA2465382A1 (en) 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
WO2003045920A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
MXPA03000966A (es) 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003227360A1 (en) 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
JP2006507294A (ja) 2002-11-07 2006-03-02 ファイザー・プロダクツ・インク 抗糖尿病剤
US7098235B2 (en) * 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
JP2004196702A (ja) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd 新規なアミド誘導体又はその塩
US7501440B2 (en) * 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
MXPA05011176A (es) 2003-04-17 2005-12-14 Pfizer Prod Inc Derivados de carboxamida como agentes antidiabeticos.
BRPI0409952A (pt) * 2003-04-30 2006-04-25 Pfizer Prod Inc agentes anti-diabéticos
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
GB0318464D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318463D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020986A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
WO2005020985A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
GB0205176D0 (en) 2002-04-17
JP2005524667A (ja) 2005-08-18
IL163823A0 (en) 2005-12-18
US7138415B2 (en) 2006-11-21
EP1483240A1 (en) 2004-12-08
PL373872A1 (en) 2005-09-19
AU2003216988A1 (en) 2003-09-16
US20050107362A1 (en) 2005-05-19
RU2004125182A (ru) 2005-06-10
CN100374420C (zh) 2008-03-12
CA2477717A1 (en) 2003-09-12
NO20044032L (no) 2004-10-05
CN1639120A (zh) 2005-07-13
NZ534683A (en) 2006-02-24
ZA200406681B (en) 2005-09-22
KR20040097145A (ko) 2004-11-17
TW200304817A (en) 2003-10-16
IS7435A (is) 2004-09-02
WO2003074484A1 (en) 2003-09-12
MXPA04008612A (es) 2004-12-06
AR038889A1 (es) 2005-02-02

Similar Documents

Publication Publication Date Title
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BR9910467A (pt) Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
GB0206860D0 (en) Compounds
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO986055L (no) Nye heterocykliske forbindelser, deres fremstilling, farmas°ytiske preparater inneholdende forbindelsene og deres anvendelse ved behandling av diabetes og beslektede sykdommer
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
BR0206955A (pt) Ligantes de receptores de canabinóides
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BR0308653A (pt) Cristais de derivado de benzeno de glicopiranosiloxibenzila
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
MA27040A1 (fr) Nucleosides substitues en 4'
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
BR9916590A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, método para a produção de um efeito anti-câncer em um animal de sangue quente, uso do derivado de pirimidina, e, composição farmacêutica
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
WO2003074513A3 (en) Indole amide derivatives and their use as glycogen phosphorylase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.